FUSION BD is designed to mine complex multiscale datasets to identify clinical and molecular phenotypes critical to biomarker discovery and drug development. FUSION BD can explore biochemical processes utilizing AI-based search techniques to simultaneously evaluate a broad range of candidate signatures for predictive value across multiple clinical parameters, high-complexity assays, and clinical endpoints. Onscreen automation options allow researchers to control exploration constraints including disease categories, patient demographics and histopathology, therapeutic schedules, standard and emerging assay types, and clinical outcomes. FUSION BD will automatically design and evaluate candidate signature-endpoint combinations based on desired performance specifications. Discovery reporting includes multivariate assessment of process characteristics, pathway involvement, and disease associations. FUSION BD can identify promising biomarker signatures and perform in silico patient screening without custom programming or costly IT support. FUSION BD is redefining how quickly clinical and molecular signatures can be identified, tested, and deployed in the research enterprise.